The financial havoc from the astronomical prices of these drugs is just too severe:
What economists know seems to consist entirely of a list of things that cannot go on forever, and this may be one of them. But if it can’t go on forever it will stop..... Herbert Stein; May 1985
Thousands in One State to Lose Weight Loss Drug Coverage
By Jordan King - June 13, 2024Thousands of people in Michigan who use popular weight loss drugs will soon lose their coverage for it.
Blue Cross Blue Shield of Michigan, the state's largest health insurer, announced it would end its funding for GLP-1 obesity drugs starting from January 1 next year.
This move will affect close to 10,000 people on these medications, according to Bloomberg.
A spokesperson for Blue Cross told Newsweek the decision came after "careful consideration of GLP-1 weight loss drugs' efficacy, safety and access, and cost."
They did not expand on what these concerns were, but research published by the insurer in May found that "most people are unlikely to see lasting benefits" from weight-loss medication.
This is because "58 percent of patients discontinue use before reaching a clinically meaningful health benefit," the research carried out by the Blue Cross Blue Shield Association (BCBSA) and conducted by Blue Health Intelligence concluded.
Vice President of Clinical Affairs at BCBSA Razia Hashmi said: "When patients take medication, we want it to be safe and effective. Unfortunately, weight loss isn't as simple as filling a prescription."
Blue Cross also changed its requirements for coverage of Saxenda, Wegovy and Zepbound from August 1 this year.
People who want the drug will have to see a prescriber in person, rather than online or over the phone, and will have to have a body mass index of 35 or higher.
Children will also no longer be able to get the drug, with the new rules making it only available to adults.
Novo Nordisk A/S, the Danish company which supplies Wegovy, told Newsweek it is "disappointed" in the move, "as it is contrary to actions that many throughout our country are taking – which is to expand coverage for these important medicines."
Newsweek has contacted Eli Lilly & Co., which supplies Zepbound, via email for any response.
Whether insurers cover weight loss medications sometimes depends on the company, an individuals coverage and the circumstances.
Healthinsurance.org tells people who are looking at different plans: "It's common for these drugs to be covered if they're prescribed for another medical condition, such as diabetes, but not if they're being used specifically for weight loss."
Medicare, the government health insurance program, does not generally cover weight-loss medications, but there can be some exceptions.
These are usually for people who have serious health conditions like diabetes or who are at cardiovascular risk.
Blue Cross' full statement said: "Blue Cross Blue Shield of Michigan is committed to providing our members with access to high-quality, affordable health care.
"We also have a responsibility, as stewards of our members' and customers' premiums, to ensure that the drugs we pay for benefit our members without adding excessive costs that impact all members and customer groups.
"Blue Cross and Blue Care Network are changing prior authorization requirements for coverage of Saxenda, Wegovy and Zepbound, beginning August 1, 2024, for our large group fully insured segment.
"Additionally, Blue Cross will end coverage of GLP-1 drugs for weight loss for large group fully insured members beginning January 1, 2025, or on a group's 2025 health coverage renewal date. Blue Cross made these changes after careful consideration of GLP-1 weight loss drugs' efficacy, safety and access, and cost."
Sponsors
Friends of MHF
Kirsten DeVries
Tom & Karen Nunheimer
Steve Ahonen
Ron & Faith Bosserman
Marlin & Kathy Klumpp
Sign Up for MHF Insights to keep up on the latest in Michigan Health Policy
